Through the acquisition Aspire Global expects to “control yet another crucial part” of the iGaming vertical, looking into creating synergies, broadening the game portfolio and providing a channel to distribute and sell propriety games outside Aspire Global’s partner network.

Pariplay has hundreds of proprietary game titles complemented by more than 2,000 games from leading third-party providers on its B2B platform. The game portfolio is certified for several regulated markets in Europe, including Denmark which will be launching shortly. Moreover, Pariplay has cleared an iGaming certification for New Jersey, which Aspire Global is expecting to leverage.

Aspire Global says the acquisition of Pariplay strengthens B2B-business through external game sales — accelerating growth, creating synergies and saving costs with an expected positive effect on overall EBITDA as of 2020. For 2019 however, the transaction is not expected to have any material effect on Aspire Global’s financial results.

“We are excited to welcome the Pariplay team to Aspire Global. The acquisition of Pariplay is in line with our M&A strategy focusing on B2B growth and external game sales,” says Tsachi Maimon, CEO at Aspire Global.

The integration of Pariplay grants us control of yet another crucial part of the iGaming value chain – cutting costs, broadening the game portfolio and providing a channel to sell and distribute propriety games outside Aspire Global network. Moreover, Pariplay holds an iGaming license for New Jersey, which could act as the spearhead of our future efforts to enter the US market,” Mr Maimon adds.

The post Aspire Global finalises Pariplay purchase first appeared on The Malta Business Weekly.

ICC added that it actively investigating complementary pharmacy related assets within Colombia that may serve as synergistic accompaniments to its acquisition of Farma Swiss.

Under the LOI, International Cannabis will issue AgraFlora a number of common shares in the capital of ICC that equals to $250,000, based upon the five-day variable weighted average price of ICC’s common shares for the five trading sessions prior to the announcement of an agreement.

“This strategic transaction further crystalises our alliance with ICC with regards our collaborative pursuit of the burgeoning global cannabis industry,” said Brandon Boddy, Chairman and Chief Executive Officer of AgraFlora Organics International.

“Monetising our flagship pharmacy operation through a trusted ally permits us to streamline our international cannabis operations while focusing on the continued retrofit of our world-class greenhouse complex in Delta, BC. We are excited to be increasing our shareholdings in ICC as they continue to execute upon their international business mandate and embark upon realising material cash flows,” he added.

“By integrating Farma Swiss’ intuitive pharmacy platform with our 13-hectare cannabis centre of excellence and preeminent catalogue of native Colombian cannabis genetics, ICC will continue to solidify its leadership position within Colombia’s highly competitive medical cannabis marketplace, while streamlining patients access to our unique formulations,” said David Shpilt, Chief Executive Officer, International Cannabis Corp.

The agreement provides International Cannabis with a Latin American brick-and-mortar presence, as well as an existing commercial agreement, further augmenting its tetrahydrocannabinol (THC) and cannabidiol (CBD) cultivation capabilities and logistical infrastructure.

ICC’s addition of a premier downstream Colombian asset conceives a compliant and secure platform for the distribution of medical cannabis and cannabinoid-derived products within Colombia.

Farma Swiss is part of Pure Grow Medicinals S.A.S. It operates a licensed pharmacy strategically situated within a high traffic, commercial neighbourhood of Medellin, Colombia.

The post ICC to buy AgraFlora’s Colombian pharmacy operation first appeared on The Malta Business Weekly.